Premium
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer
Author(s) -
Lee JinGyun,
McKinney Kimberly Q.,
Mougeot JeanLuc,
Bonkovsky Herbert L.,
Hwang SunIl
Publication year - 2013
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201300248
Subject(s) - sunitinib , imatinib mesylate , imatinib , pancreatic cancer , dasatinib , cancer research , pharmacology , chemistry , synthetic lethality , cancer , medicine , dna repair , biochemistry , myeloid leukemia , gene
In the present study, proteomic analysis was performed to discover combinational molecular targets for therapy and chemoresistance by comparing differential protein expression from Panc‐1 cells treated with FDA‐approved drugs such as sunitinib, imatinib mesylate, dasatinib, and PD184352. A total of 4041 proteins were identified in the combined data from all of the treatment groups by nano‐electrospray ultra‐performance LC and MS/MS analysis. Most of the proteins with significant changes are involved in apoptosis, cytoskeletal remodeling, and epithelial‐to‐mesenchymal transition. These processes are associated with increased chemoresistance and progression of pancreatic cancer. Among the differentially expressed proteins, heme oxygenase‐1 (HO‐1) was found in the sunitinib and imatinib mesylate treatment groups, which possibly acts as a specific target for synthetic lethality in combinational treatment. HO‐1 was found to play a key role in sensitizing the chemoresistant Panc‐1 cell line to drug therapy. Viability was significantly decreased in Panc‐1 cells cotreated with sunitinib and imatinib mesylate at low doses, compared to those treated with sunitinib or imatinib mesylate alone. The results suggest that induction of chemosensitization by manipulating specific molecular targets can potentiate synergistic chemotherapeutic effects at lower, better tolerated doses, and in turn reduce the toxicity of multidrug treatment of pancreatic cancer.